|
Doxorubicin hci |
|
On diuretics : get electrolyte levels aster's usmle step3 notes page 62 of 94 may 19, 2003 avoid elective surgery in patients with significant hepatic dysfunction indications for intra-op insulin - iddm : any surgical procedure - niddm on insulin : any surgical procedure - niddm on oha : major surgical procedure prophylactic preop antibiotics only decrease the incidence of wound infection no effect on postop pneumonia, uti, sepsis ; : cefazolin is a good choice elderly with repeated falls with dementia seizures: look for chronic sdh stool impaction can cause urinary incontinence breast cancer with brca1 gene: better prognosis breast cancer with her2 neu gene: poor prognosis kaposi's: hhv8 male homosexuals ; cyclophosphamide: mesna methotrexate: leucovorin cisplatin: amifostine doxorubicin: dexrazoxane mx of chemotherapy induced dry mouth: pilocarpine hcl 5-10 mg po tds assessment of doxorubicin toxicity: muga scan neutropenia: requires antibiotic prophylaxis for g - ; fungus competent individuals the end of life have right to refuse nutrition and hydration cutaneous absorption of drugs is 3 times more in children than in adults topical drugs c i in pregnancy podophyllin isotretinoin lindane aster's usmle step3 notes page 63 of 94 may 19, 2003 most appropriate initial investigation in -thalassemia: cbc with red cell indices sle: decreased c3 c4 dumping syndrome post-bilroth ii - dietary modification - octrotide - fails ; bilroth i conversion 75%-95% of aaas are infra-renal - dx: u s abdo.
The dosage amount of doxorubicin is preferably in the range from 30 to 100 mg m.
1. 2. 15 Grams. All except meats. Most vegetables have little carbohydrate except starchy vegetables, like peas, corn and lima beans. 3. 4 carbohydrate choices. 4. Use low calorie, thin sliced bread. 2 slices 1 carbohydrate choice. Put tuna salad and tomatoes on lettuce and have 5 crackers instead of the bread. 5. Use low fat or no fat mayonnaise. Use 1% or fat free milk. Choose a lower fat bread How did you do? If you are a bit overwhelmed or confused, call ECDA and ask to be notified when the next Dining With Diabetes or The Healthy Diabetes Plate programs will be offered. We will personally notify you when they are scheduled.
Higher for doxorubicin 287 mg m squared versus 257 mg m squared ; and epirubicin 480 mg m squared versus 422 mg m squared ; , dr.
Continued from page 681 ; be even better. The specificity of car hon-il methyl-bromo-LSD for 52 sero tonin receptors was indicated by the blocking effect of the drug ketanserin.
EARN UP TO 0 WEEKLY Helping the government. PT No Experience. Excellent Opportunity. Call Today! 1-800-488-2921. Ask for Department J19. FEE REQUIRED and dronabinol.
Ity, but to a great extent also structural factors as such are of essential importance. We have identified such factors in two important groups of cytostatics, namely anthraquinone and acridine compounds Stefanska et al., 1999 ; . According to our concept, the inclusion into their molecules of one or two fused five- or six-membered heterocyclic ring s ; makes these molecules able to overcome MDR. This is an indispensable qualitative factor, while the modification of lipophilicity of such compounds by appropriate substituents can further quantitatively influence their activity towards MDR cells. This hypothesis has led to the development of several novel groups of active polycyclic anthraquinone and acridine analogues Fig. 2 and references there ; . It has been evidenced that polycyclic compounds of such type overcome MDR due to the speed of their uptake surpassing the rate of MDR transporters-mediated efflux Tkaczyk-Gobis et al., 2001; Tarasiuk et al., 2002; 2004; Fig 1: Borowski et al., 2004 ; . The cytotoxic activity of representative compounds Fig 1: Borowski et al., 2004 ; from several groups of polycyclic anthraquinone and acridine analogues towards Pgp and MRP cell lines is presented in Fig. 3. It should be noted that the compounds examined have very favorable resistance indexes in both types of resistant cells, as compared to those of the reference compounds doxorubicin and mitoxantrone. As exemplified in Fig. 4A the initial velocities of uptake and cellular accumulation of a tetracyclic anthraquinone analogue in sensitive cells are much be er than in the case of the reference tricyclic idarubicin. An exemplary experiment with a pentacyclic acridine ana.
Doxorubicin heart failure
Valuations of the 2006 leadership training are in -and the survey says it was a day well spent on learning the skills and gathering the knowledge needed to be a leader in the breast cancer community in both advocacy and fundraising and dss.
Increased workload refers to the increased number of activities required to care for HIV AIDS patients. Caring for these patients can be physically and psychologically exhausting. Moetlo 1998: 15 ; , Sminoff, Erlen and Sereika 1998: 148 ; , Mahatelo 2003: 7 ; and Kemppainen 1996: 296 ; support the idea that nursing AIDS patients requires more nursing care than other patients because the majority of them are very weak, bed-ridden and need everything done for them. An increased workload as a result of HIV AIDS could increase the risk of contracting HIV-infection. Working.
G.D. SEARLE & CO., 5200 Old Orchard Road, Skokie, Illinois, United States of America. Address for service is c o F.R. KELLY & CO., 27 Clyde Road, DUBLIN 4, Ireland and dulcolax.
Their legitimacy. Wholesalers and retailers should keep a detailed record to be able to recall a drug if necessary and employ qualified people to fill supervisory posts. Health professionals are required to be on alert for any failure of a drug to bring about effective treatment and encourage their members to use only trusted sources of supply. Consumers should be educated to adhere to their physician's instructions. In addition, patients should be informed of expectations of the treatment and also of adverse effects. Consumers should also be educated as to the problem of counterfeiting, specifically to not mistrust the health professional when a treatment does not work as anticipated. They must also be educated to report it to the healthcare professional, and not panic when a drug alert is announced. In Cambodia, a strategy of improving the availability of quality assured drugs and a poster and radio campaign has educated patients to distinguish fake tablets and has further harmed the counterfeit anti-malarials trade.25 Added to these measures is the fact that all of these agencies and groups of people should have constant communication with the DRA and report any anomaly discovered in any pharmaceutical product. The high prices of branded pharmaceuticals in the market are one of the primary reasons that the counterfeit drug trade flourishes, not only in SouthEast Asia but in the US and Europe as well. According to Dr Suzuki, "A deadly combination of demand for cheap drugs and fat profit margins makes counterfeit drugs irresistibly attractive to greedy criminals".26 Counterfeiting has been rampant in developing countries and is linked to organised crime, unregulated trade, weak punishment and corrupt politicians, etc. To combat counterfeiting, which exists only if it is attractive criminal activity, measures should be taken to reduce the comparative desirability of counterfeiting for the offenders. "All measures that reduce the profit margins for manufacturing fakes, such as reducing the price and increasing the availability of genuine, quality assured drugs, will make counterfeiting a less attractive criminal activity."27 An investment devoted to defeating this problem must be made physically and financially. This can be carried out by a combination of using the nation's resources and the resources of the pharmaceutical industry. In the long run, this would offset the US billion loss that the pharmaceutical industry is estimated to be incurring due to the counterfeit trade. Technological advancements in drug manufacturing and delivery are an important line of defence against counterfeit drugs. These counterfeit deterrents must be state of the art and changed often. Holograms and fluorescent markers are effective high-tech.
Liposomal doxorubicin
Ss PREDICTORS OF COMPLIANCE ON COMBINATION ANTIHYPERTENSIVE THERAPY IN A MEDICAID POPULATION Shaya FT * , El Khoury AC, Fatodu H, Garber H, Zacker C, Frech-Tamas F, Ngan GC. Department of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, 515 West Lombard St., #256, Baltimore, MD 21201; fshaya rx.umaryland , 410 ; 706-5392 OBJECTIVE: To identify predictors of compliance on antihypertensive combination pharmacotherapy in a Medicaid population. METHODS: Retrospective medical and pharmacy claims data analysis for Maryland Medicaid patients who were prescribed combinations of angiotensin-converting enzyme inhibitor hydrochlorothiazide ACEI HCTZ ; or angiotensin-converting enzyme inhibitor calcium channel blockers ACEI CCBs ; during the period of January 1, 2002-December 31, Inclusion: continuously enrolled patients, 18 years and older, with at least 1 year of follow-up. Exclusion: use of antihypertensive drugs between January 1 and June 30, 2002 to obtain incident cohort ; . Compliance was measured by the medication possession ratio with a cut-point of 80%. Multivariate logistic regression was used to predict compliance as a function of age, gender, race, comorbidities Charlson Comorbidity Index or CCI ; , and use of either fixed-dose pill or 2 concurrent pill combination therapies. RESULTS: Total of 568 patients, 63.73% females, 68.84% African Americans, median age 52 years, 35.56% on fixed-dose combination therapy, 72.89% started on ACEI HCTZ, 24.82% complied with therapy. Patients younger than 40 years odds ratio [OR] 0.45; P 0.03, confidence interval [CI], 0.22-0.91 ; , and African Americans OR 0.47, P 0.0006; CI, 0.31-0.73 ; are less likely to be compliant than patients older than 60 years, and whites, respectively. Those who have a CCI of 1 OR 2.03; P 0.052; CI, 0.99-4.15 ; and those on fixed-dose combination drugs OR 1.55; P 0.03; CI, 1.03-2.32 ; are more likely to be compliant than those with higher CCI and those on 2 concurrent pill therapies, respectively. CONCLUSION: Age, race, comorbidities, and drug-simplified regimen are significant predictors of compliance. These results may inform medication therapy management programs. ss PREVALENCE OF BARRIERS TO MEDICATION ADHERENCE FOR PATIENTS WITH ASTHMA OR DEPRESSION Skinner EP * , Yu-Isenberg KY * , Hahn SR, Priest JL, Weaver MB, Olson PS. GlaxoSmithKline, 5 Moore Dr., Research Triangle Park, NC 27709; Elizabeth.p.skinner gsk , 919 ; 483-5998; Kristina.s.yu-isenberg gsk , 919 ; 483-2121 OBJECTIVE: To evaluate the prevalence of barriers to adherence identified with the ASK-20 Adherence Starts With Knowledge ; survey in a cohort of patients with asthma or depression. METHODS: This analysis is based on a sample of randomly and duragesic.
The flood problems that occur either naturally or cause by the man's activities are both bringing a lot of inconvenience to the residents. Government need to cover all the expenses of repairing the damages cause by the flood. Besides that, government also needs to supply the medical facility, temporary accommodations and food for the victims.
Reverse doxorubicin resistance
Be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise without the prior permission of Emergency Medicine Journal. N Authors are required to grant Emergency Medicine Journal an exclusive licence to publish; further details available online at : emj ifora N Emergency Medicine Journal is published by BMJ Publishing Group, typeset by The Charlesworth Group and Printed in the UK on acid-free paper by Cambrian Printers Ltd, Aberystwyth N Periodicals postage paid, Rahway, New Jersey, USA. Postmaster: send address changes to: Emergency Medicine Journal, c o Mercury Airfreight International Ltd, 365 Blair Road, Avenel, NJ 07001, USA and echinacea.
Doxorubicin feline
4. Vassalle M, Cummings M, Castro C, Stuckey JH: The relationship between overdrive suppression and overdrive excitation in ventricular pacemakers in dogs. Circ Res 1976; 38: 367 Vassalle M: The relationship among cardiac pacemakers. Circ Res 1977; 41: 269 Gorgels APM, DeWit B, Beekman HDM, Dassen WRM, Wellens HJJ: Effect of overdrive stimulation on the normal idioventricular rhythm, in Gorgels APM ed ; : Ventricular impulse formation and the influence of digitalis intoxication thesis ; . Maastricht, The Netherlands, University of Limburg, 1985 7. Gorgels APM, DeWit B, Beekman HDM, Dassen WRM, Wellens HJJ: Effect of lidocaine, verapamil, isoprenaline and ouabain on ventricular impulse formation following ventricular stimulation, in Gorgels APM ed ; : Ventricular impulse formation and the influence of digitalis intoxication thesis ; . Maastricht, The Netherlands, University of Limburg, 1985 8. Vassalle M, Knob RE, Cummings M, Lara GA, Castro C, Stuckey JH: An analysis of fast idioventricular rhythm in the dog. Circ Res 1977; 41: 218 Ilvento JP, Provet J, Danilo P Jr, Rosen MR: Fast and slow idioventricular rhythms in the canine heart: A study of their mechanism using antiarrhythmic drugs and electrophysiologic testing. J Cardiol 1982; 49: 1909 Binah 0, Cohen IS, Rosen MR: The effects of adriamycin on normal and ouabain-toxin canine Purkinje and ventricular muscle fibers. Circ Res 1983; 53: 655 LeMarec H, Spinelli W, Rosen MR: The effects of doxorubicin on ventricular tachycardia. Circulation 1986; 74: 881 LeMarec H, Dangman K, Danilo P, Rosen M: An evaluation of automaticity and triggered activity in the canine heart one to four days after myocardial infarction. Circulation 1985; 71: 1224 Bigger JT, Bassett AL, Hoffman BF: Electrophysiologic effect of diphenylhydantoin on canine Purkinje fibers. Circ Res 1968; 22: 221 Rosen MR, Gelband H, Hoffman BF: Correlation between effects of ouabain on the canine electrocardiogram and transmembrane potentials of isolated Purkinje fibers. Circulation 1973; 47: 65 Rosen MR, Hordof AJ, Ilvento JP, Danilo P Jr: Effects of adrenergic amines on electrophysiological properties and automaticity of neonatal and adult canine Purkinje fibers: Evidence for a- and fi-adrenergic actions. Circ Res 1977; 40: 390 Hamra M, Danilo P Jr, Rosen MR: Developmental changes in the effects of nadolol on adult and canine Purkinje fibers. Dev Pharmacol 1988; 11: 155 Mary-Rabine L, Rosen MR: Lidocaine effects on action potentials of Purkinje fibers from neonatal and adult dogs. J Pharmacol Exp Ther 1977; 205: 204 Dangman KH, Hoffman BF: Antiarrhythmic effects of ethmozin in cardiac Purkinje fibers: Suppression of automaticity and abolition of triggering. JPharmacol Exp Ther 1983; 277: 578 Snedecor GW, Cochran WG: Statistical Methods. Ames, Iowa, Iowa State University Press, 1967 20. Dangman KH, Hoffman BF: Studies on overdrive stimulation of canine Purkinje fibers: Maximum diastolic potential as a determinant of the response. JAm Coil Cardiol 1983; 2: 1183 Rosen MR, Danilo P Jr: Digitalis-induced delayed afterdepolarizations, in Zipes DP, Bailey JC, Elharrar V eds ; : The Slow Inward Current and CardiacArrhythmias. The Hague, Martinus Nijhoff Publishing, 1980, pp 417-436 22. Davis LD, Temte JV: Electrophysiological action of lidocaine on canine ventricular muscle and Purkinje fibers. Circ Res 1969; 24: 639 Rosen MR, Danilo P Jr: Effects of tetrodotoxin, lidocaine, verapamil and AHR-2666 on ouabain induced delayed afterdepolarizations in canine Purkinje fibers. Circ Res 1979; 46: 117 Kline RP, Cohen I, Falk R, Kupersmith J: Activity-dependent extracellular K' fluctuations in canine Purkinje fibers. Nature 1980; 286: 68 Hewett K, Gessman L, Rosen MR: Effects of procainamide, quinidine and ethmozin on delayed afterdepolarizations. EurJ Pharmacol 1983; 96: 21.
Cumulative doxorubicin dose
Atmosphere of the `Damascus Spring' which followed the succession of his son Bashar gave further impetus to Kurdish political activity. Kurdish political organizations were able to meet more openly and increase their activity and support. The regime also relaxed its attitude towards Kurdish publications and music and the burgeoning number of illegal private Kurmanji language classes. Official concern about the problem posed by the Kurds became apparent from several secret meetings between government officials and Kurdish party leaders. Despite the slight softening of the government's approach in some areas since 2000, it has also maintained and even increased its repression of Kurdish expression and of the Kurdish movement. In Bashar al-Asad's five years in power, Kurdish activists have been repeatedly intimidated and detained while anti-Kurdish rhetoric and restrictions on Kurdish activity remain firmly in place. It seems the regime is prepared to make some conciliatory and positive public statements in an attempt to subdue the Kurds and ease international pressure, but that in practice it is unwilling to countenance any real change. Two leaders of the Kurdish Union Party in Syria Yekiti Party ; , Marwan Othman and Hasan Salih, became prominent political prisoners after being arrested in 2002. They were detained for 14 months for organizing a human rights demonstration in Damascus.11 The official expulsion of the PKK from Syrian territory in 1998 freed the Syrian Kurds from the complication of PKK presence, but it is developments in Iraq that have been and remain of greatest significance. International intervention in the war of 1991 and the subsequent autonomy gained by Iraqi Kurds were watched closely by Syrian Kurds, who felt more emboldened to articulate their demands. The fall of Saddam Hussein in 2003 and subsequent gains made by the Iraqi Kurds at both regional and national levels have provided massive encouragement. Furthermore, international pressure greatly increased on the isolated Syrian regime on issues of terrorism, the Iraq border and interference in Lebanon, leaving the Syrian government weakened and aware that repression of internal dissent would attract further international condemnation. The Iraq war of 2003 heightened tension between Kurds and Arabs in Syria as Arabs accused Kurds of treacherously supporting a US-led war against a brother Arab nation. The Kurdish response was more complicated. Many supported the war out of solidarity with the Iraqi Kurds and hatred of Saddam Hussein. George Bush's name has been invoked in slogans, but many Kurds, including the politically active, have little faith in US initiatives in the region and do not see an alliance with the US as the answer to their problems.12 For its part, the US, despite its tough rhetoric towards Syria, has adopted a low-key approach to the Syrian Kurds. As an issue on its list of complaints, their situation has fallen well behind Lebanon and the Hariri assassination, the Iraq border and support for terrorism. It is probable that the US does not push the Kurdish issue in Syria because it is concerned about further regional instability and its valued relationship and efalizumab.
Doxorubicin chemotherapy
In addition, the results showed that the degradation products of paca mainly polycyanoacrylic acid ; in the presence of doxorubicin are able to increase both accumulation and cytotoxicity, thus suggesting the formation of a doxorubicin-polycyanoacrylic acid ion pair and doxorubicin.
| Conversion of daunorubicin to doxorubicinAged 65 years who are in good physical and cardiac function. Patients aged 65 years may also be eligible for ASCT if they are in very good health. Nontransplant Candidates. Patients who are not candidates for ASCT often receive a combination of melphalan and prednisone. Other combinations of agents, including cyclophosphamide and prednisone CP ; may also be used. High-dose dexamethasone or combination thalidomide THALOMID ; and dexamethasone are often used in older patients who may be unable to tolerate other therapies. Initial therapy in these patients is typically continued for approximately 12 months or until their response to therapy has leveled off. At this point, patients usually receive some form of maintenance therapy for their disease. However, patients do not always respond to initial therapy, and even if they do, relapse is inevitable. These patients with refractory disease are in need of salvage treatments. Transplant Candidates. Alkylating agents such as melphalan may impair the ASCT process and often necessitate the use of alternate treatments as induction therapy prior to transplant. Alternate treatments include dexamethasone; combination thalidomide and dexamethasone; or the vincristine, doxorubicin, and dexamethasone VAD ; chemotherapy regimen. The VAD regimen may also be modified using liposomal doxorubicin DOXIL ; , vincristine, and short-schedule dexamethasone DECADRON ; DVd ; . After 3 or 4 cycles of induction therapy to minimize tumor burden, stem cells are commonly collected from transplant candidates for use in the procedure. Newer agents, such as oral lenalidomide REVLIMID ; and bortezomib for injection VELCADE ; , are currently under investigation for use prior to ASCT. Salvage Treatments. Patients with relapsed and or refractory disease are requiring of salvage therapy. The initial therapy may be reconsidered if a relapse occurs after 6 months of discontinuing therapy. Other options include various salvage chemotherapy agents or combinations, thalidomide-based regimens, VELCADE, or REVLIMID. per patient , 000 ; that is typically considered to be warranted due to improved survival rates associated with the combination.5 Considering that most salvage treatments are based on regimens used in induction treatment and basically carry the same cost, similar figures as those mentioned earlier may be used in pharmacoeconomic analyses. The IMiD compounds, such as THALOMID and REVLIMID, carry the highest acquisition costs , 295 year and , 183 year, respectively ; , but have also demonstrated improved survival rates over other older agents and regimens.6, 7 VELCADE is another newer agent associated with improved survival rates over older, standard regimens, and is associated with a much lower annual cost of , 120.8, 9 Interestingly, the discrepancy in the AWP of VELCADE compared with that of THALOMID has grown since 2003, with significantly greater price increases for THALOMID Table 1 ; . Pharmacoeconomic analyses comparing the newer, higher-priced agents with the less-costly standard regimens like bortezomib for injection are necessary in managed care to determine the costeffectiveness of the novel agents. Headto-head trials between the newer agents would also serve in assisting stakeholders in determining the survival benefit of each agent. Until enough of this data is available on which to base sound decisions, treatment algorithms may assist in guiding clinicians along the most appropriate course of therapy, thereby avoiding unnecessary costs and eletriptan.
Doxorubicin ndc
Give particulars of the product source, formulation and specifications ; , if different from that proposed for marketing. Give particulars source, formulation, characteristics, packaging etc ; of placebos, controlling agents, if any. If product used is different from that proposed for marketing registration ; , the equivalence of the products should be discussed and appropriate data included providing evidence of equivalence. 2. Particulars of subjects.
Scintillation cocktail PicoFluor-40, Packard ; , before assaying in scintillation counter Packard ; . Percentage of inhibition was calculated according to the following formula : 1 cpm agonist-cpm basal ; cpm forskolin-cpm basal x100, where cpm basal was determined in a medium containing only IBMX and cpm forskolin in the presence of forskolin + IBMX. All experiments were carried out in triplicate and elidel.
|
Q. Huang, J. Lyon, H. Hamadeh, E. Herman, M. Embry, S. Pettit, B. Gollapudi, S. Lipshultz, R. Roth, P. Ciaccio, T. Auman, Y. Bauer, M. Cunningham, J. Davis, G. Gibson, W. Harrouk, R. Haworth, M. Holsapple, A. Klenk, J. Leighton, G. Orphanides, R. Paules, F. Staedtler, S. Thurmond and J. Tugwood. Mechanism-Based Markers of Toxicity Working Group, HESI Committee on the Application of Genomics in Mechanism-Based Risk Assessment, International Life Sciences Institute, Washington, DC. This study was initiated by the Mechanism-Based Markers of Toxicity Working Group as part of the HESI Committee on the Application of Genomics in Mechanism-Based Risk Assessment. Doxorubicin Dox ; , a broad spectrum anthracycline antineoplastic agent, is associated with a cumulative dose-dependent cardiomyopathy in patients. In the current study, the cardiotoxicity potential of Dox was investigated and compared with the effects of etoposide Etop ; , a pharmacologically comparable negative control. Sprague Dawley rats received weekly intravenous dosing of Dox 0.5, 1, 2, and 3 mg kg week ; or Etop 0.5, 1, and 3 mg kg week ; for 6 consecutive weeks. The highest dose of Dox was associated with low incidence of mortality and dose-dependent decrease in body weight gain was observed in animals that received Dox. Dox treatment caused profound pancytopenia RBC, WBC and lymphocyte ; , and prominent changes in various serum chemistry parameters BUN, CREA, ALKP, CHOL, and ALB ; . Cardiotoxicity markers, such as creatinine kinase CK ; , CKMM and troponin T, were elevated in the animals receiving Dox at doses of 2 and 3 mg kg. Dexrazoxane Dex ; , a protective agent for Dox induced cardiotoxicity, significantly ameliorated Dox's effects on body weight, serum parameters, and cardiotoxicity markers. Histopathological examination of toluidene-blue stained heart sections revealed macrovesicular vacuolation of atrial and ventricular myocytes following high dose Dox. High-density gene expression profiles will be analyzed to study the molecular mechanisms underlying the cardiotoxic effects mediated by Dox and inform for potential safety biomarkers and dronabinol.
Doxorubicin chop
1. Holmes FA, Walters RS, Thenault RL et al. Phase II trial oftaxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991; 83: 1797-805. Reichman BS, Seidman AD, Crown JPA et al. Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 1993; 11- 1943-51. Seidman AD, Reichman BS, Crown JPA et al. Paclitaxel as second and subsequent therapy for metastatic breast cancer: Activity independent of prior anthracycline response. J Clin Oncol 1995; 13: 1152-9. Seidman AD.Tiersten A, Hudis C et al. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol 1995; 13: 2575-81. Holmes FA, Frye D, Valero Vet al. Phase I study of Taxol T ; and doxorubicin D ; with G-CSF in patients PT ; without prior chemotherapy CT ; for metastatic breast cancer. Proc Soc Clin Oncol 1992; 11: 60 Abstr 66 ; . 6. Sledge G, Robert N, Sparano J et al. Eastern Cooperative Oncol and eligard
1. National Comprehensive Cancer Network Proceedings: NCCN practice guidelines for upper gastrointestinal carcinomas. Oncology, 12: 179-223, 1998. Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PO, Haglund U, Svensson C, Enander LK, Linne T, Sellstrom H, Heuman R: Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol, 8: 163-168, 1997. Murad A, Santiago F, Petroianu A, Rocha PR, Rodrigues MA, Rausch M: Modified therapy with 5-fluorouracil, doxorubicin and methotrexate in advanced gastric cancer. Cancer, 72: 37-41, 1993. Pyrhonene S, Kuitunen T, Kouri M: A randomized phase III trial comparing fluorouracil, epidoxorubicin and methotrexate FEMTX ; with best supportive care in non-resectable gastric cancer. Ann Oncol, 3 suppl 5 ; : abstr 47, 1992. 5. Wils J, Bleiberg H: Current status of chemotherapy for gastric cancer. Eur J Cancer Clin Oncol, 25: 3-8, 1989. Loehrer PJ Sr, Harry D, Chlebowski RT: 5-fluorouracil vs epirubicin vs 5-fluorouracil plus epirubicin in advanced gastric carcinoma. Invest New Drugs, 12: 57-63, 1994. Cunningham D, Soukop M, McArdle CS, Carter DC, Smyth JF, Allan SG, Kaye SB, Sangster G, Calman KC: Advanced gastric cancer: experience in Scotland using 5-fluorouracil, adriamycin and mitomycin-C. Br J Surg, 71: 673-676, 1984. Haim N, Cohen Y, Honigman J, Robinson E: Treatment of advanced gastric carcinoma with 5-fluorouracil, adriamycin and mitomycin-C FAM ; . Cancer Chemother Pharmacol, 8: 277-280, 1982. Haim N, Epelbaum R, Cohen Y, Robinson E: Further studies on the treatment of advanced gastric cancer by 5-fluorouracil, adriamycin doxorubicin ; and mitomycin C modified FAM ; . Cancer, 54: 1999-2002, 1984. Wils JA, Klein HO, Wagener DJ, Bleiberg H, Reis H, Korsten F, Conroy T, Fickers M, Leyvraz S, Buyse M: Sequential high-dose methotrexate and fluorouracil combined with doxorubicin A step ahead in the treatment of advanced gastric cancer. A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol, 9: 827-831, 1991. Bajetta E, Di Bartolomeo M, De Braud F, Bozzetti F, Bochicchio AM, Comella P, Fagnani D, Farina G, Ferroni C: Etoposide, doxorubicin and cisplatin EAP ; treatment in advanced gastric carcinoma: a multicenter study of the Italian Trials in Medical Oncology ITMO ; Group. Eur J Cancer, 30A: 596600, 1994. Di Bartolomeo M, Bajetta E, De Braud F, Bochicchio AM, Gebbia V, Bozzetti F, Doci R, Bonfanti G, Cozzaglio L: Phase II study of the etoposide, leucovorin and fluorouracil combination for patients with advanced gastric cancer unsuitable for aggressive chemotherapy. Oncology, 52: 41-44, 1995. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M: Modified therapy with 5-fluorouracil, doxorubicin and methotrexate in advanced gastric cancer. Cancer, 72: 37-41, 1993. Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, Hughes M, Mansi J, Findlay M, Hill A, Oates J: Randomized trial comparing epirubicin, cisplatin and fluorouracil versus fluorouracil, doxorubicin and methotrexate in advanced esophagogastric cancer. J Clin Oncol, 15: 261-267, 1997. Vanhoefer U, Rougier P, Wilke H, Ducreux MP, Lacave AJ, Van Cutsem E, Planker M, Santos JG, Piedbois P, Bodenstein H, Schmoll HJ, Bleiberg H, Nordlinger B, Couvreur ML, Baron B, Wils JA: Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil and doxorubicin versus etoposide, leucovorin and fluorouracil.
Doxorubicin and cardiotoxicity
Doxorubicin weekly
Excision of neuroma, god bless you prayer, femara canada, debridement site reference.com and breastfeeding your adopted baby. Malformation of uterus, miasma greek myth, anesthetic recovery and probability model or cyanide tab.
Pegylated doxorubicin hcl liposome
Doxoruhicin, doxirubicin, doxoruubicin, doxorunicin, doxorbuicin, doxorubidin, doxorubiin, doxorjbicin, soxorubicin, doxorubicih, foxorubicin, dooxorubicin, doxroubicin, doorubicin, dooxrubicin, doxo5ubicin, doxorubcin, doxorubickn, doxourbicin, doxorub9cin.
Doxorubicin body weight
Doxorubicin heart failure, liposomal doxorubicin, reverse doxorubicin resistance, doxorubicin feline and cumulative doxorubicin dose. Doxorubicin chemotherapy, conversion of daunorubicin to doxorubicin, doxorubicin ndc and doxorubicin chop or doxorubicin and cardiotoxicity.
|
|
|
